Critical Outcome Technologies Inc. to Advance HIV-1 Integrase Inhibitor Program with a Major Pharmaceutical Company

Abstract

Upon completion of synthesis, the major pharmaceutical company will manage, conduct and fund agreed upon preliminary preclinical experiments as part of its evaluation of COTI's compounds. Once the final experiments have been completed and the results have been received by COTI, the major pharmaceutical company will have an exclusive time period to negotiate a licensing agreement with COTI for the select compounds. If an agreement is not reached within this period, COTI will be able to engage other potential partners for its HIV-1integrase inhibitor program.